PB
Paradigm Biopharmaceuticals Limited
PBIGF · OTC
$0.18 -3.16% (-$0.01)
1M +84.00%
Market Cap $159.0M
P/E Ratio -
Div. Yield -
ROE 347.77%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 1,987.14x
P/B 45.89x
P/E N/A
Growth
0 /100
Declining Book val. growth 59.88%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 102.77%
Net margin 70,283.80%
Op. margin 76,248.10%
Quality
0 /100
Poor ROIC 484.07%
ROE 347.77%
ROA 184.36%
Debt
17 /100
High Debt/Equity 2.16x
Current ratio 1.10x
Int. coverage -24.83x
Stability
19 /100
Unstable Beta -0.02x
EPS volatility 121.06%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o PBIGF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul John Rennie
Employees
8
Headquarters
Melbourne
Nadchodzące wydarzenia
24 LUT
Earnings
Upcoming earnings report